Physicians' Academy for Cardiovascular Education

Comprehensive safety analysis of PCSK9 antibody confirms positive benefit-risk profile

Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

Literature - Toth PP, Descamps O, Genest J, et al. - Circulation 2017; published online ahead of print

Main results

Conclusion

A pooled analysis of data of more than 6000 patients confirmed the safety and tolerability of evolocumab, which was not associated with a significant risk for hepatotoxicity, muscle-related AEs, or neurocognitive events. These findings support the positive benefit-risk profile of evolocumab.

References

Show references

Find this article online at Circulation

Share this page with your colleagues and friends: